Key result
Acute treatment with etanercept reduced circulating tumor necrosis factor levels and restored responding for electrical brain stimulation in a rat model of heart failure-induced anhedonia.
Why the study?
Does acute treatment with etanercept improve anhedonia in a rat model of heart failure?
Does acute treatment with etanercept improve anhedonia in a rat model of heart failure?
In a rat model of heart failure, TNF antagonism with etanercept reversed anhedonia, suggesting a role for proinflammatory cytokines in the comorbidity of cardiovascular disease and depression.
Should not change clinical practice for anhedonia in heart failure; leaves open whether TNF antagonism benefits patients with comorbid cardiovascular disease and depression.
Immune system dysfunction is hypothesized to influence several disease states, including cardiovascular disease and psychological depression. The comorbidity of depression and coronary artery disease may be influenced by immune system-brain interactions involving proinflammatory cytokines. The present studies evaluated an index of depression in a rodent model of heart failure by measuring responses to rewarding electrical brain stimulation, which provides an experimental procedure to operationally define anhedonia in rats. Heart failure led to a rightward shift in the current-response relationship in the brain stimulation paradigm, indicative of reduced rewarding properties of the brain stimulation (i.e., anhedonia). Acute treatment with a tumor necrosis factor antagonist, etanercept, reduced circulating tumor necrosis factor- levels in rats with heart failure and restored responding for electrical brain stimulation. The current findings have implications for the study of pathophysiological mechanisms underlying the association of cardiovascular disease and depression.
No takes yet. Share an insight, caveat, or question.
Grippo et al. (2003) studied Heart failure and anhedonia. Etanercept was evaluated on Responses to rewarding electrical brain stimulation and circulating tumor necrosis factor levels. Acute treatment with etanercept reduced circulating tumor necrosis factor levels and restored responding for electrical brain stimulation in a rat model of heart failure-induced anhedonia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: